We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Review Provides Insight into Therapeutic Interventions

By LabMedica International staff writers
Posted on 21 Aug 2017
A new review has outlined recommendations and a gold standard for identifying at-risk patients who are critically ill, or in receipt of organ transplants, for preventing, diagnosing and treating invasive fungal infections. More...
It was published as part of a set of papers intended to provide new insights into the breadth of serious fungal diseases and as a call to world health bodies to prevent millions of infections each year.

Invasive fungal infections, overall, are a major problem in both developed and developing countries, killing more than 1.5 million people annually. The cost to the global healthcare system runs into billions of dollars each year. Fungal infections invading the bloodstream, lungs, or other organs can cause prolonged illness and in extreme cases can lead to permanent disability or even death. Since a significant proportion of these infections is preventable, it is particularly important to improve capability to identify patients at high risk of contracting them.

The review was conducted collaboratively by researchers in Australia and Brazil. “These new insights into diagnosing and treating invasive fungal infections are significant because early and correct treatment clearly leads to better outcomes for the patient,” said senior author Prof. Tania Sorrell of Westmead Institute for Medical Research (Westmead, Australia) and of the University of Sidney Marie Bashir Institute for Infectious Diseases and Biosecurity (Sidney, Australia), “Blood infections such as candidaemia and lung infections such as aspergillosis have high mortality rates of up to 85% in critically ill and immune-compromised patients.”

“The research that has informed the recommendations in this paper will play an important role in educating doctors in both developed and developing countries about these diseases and outlining available diagnostic and therapeutic options in different medical contexts,” said Prof. Sorrell, “It will allow clinicians to tailor their approach to managing these infections in different countries or when working with specific at-risk populations.”

The study, by Colombo AL et al, was published July 31, 2017, in the journal The Lancet Infectious Diseases.

Related Links:
Westmead Institute for Medical Research
University of Sidney Marie Bashir Institute for Infectious Diseases and Biosecurity

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The platform analyzes cell-free DNA in blood, searching for minute amounts of tumor-derived fragments among background DNA (Image Credit: Adobe Stock)

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.